Patients with MS show reduction in symptoms during drug trial

Genzyme announces results of phase-3 trial of Aubagio

CAMBRIDGE, Mass. — An experimental drug for multiple sclerosis produced a noticeable reduction in symptoms of the disease in a late-stage clinical trial, the drug's developer said Friday.

Genzyme, a unit of French drug maker Sanofi, announced results from a phase-3 study of Aubagio (teriflunomide) in patients with relapsing forms of MS. According to the study, patients taking the drug in the 14-mg strength experienced a 36.3% reduction in annualized relapse rates and 31.5% reduction in the risk of sustained accumulation of disability over a 12-week period.

The study enrolled 1,169 patients who received once-daily doses of Aubagio in the 7-mg or 14-mg strength or placebo. After completing the approximately 18-month trial, patients were followed for 48 to 173 weeks.

In the treatment group that received the 7-mg strength of the drug, there was a 22.3% reduction in annualized relapse rate, but no statistically significant difference between the lower dose and placebo for the risk of 12-week sustained accumulation of disability.

Poll

Poll

SPECIAL REPORTS

Are we in the midst of a beauty revolution? Perhaps. It is no secret that the ever-changing beauty category is all about trends, but one could argue that we are embarking on an especially interesting time in beauty as technology is changing the way consumers shop and new innovations strive to break through the noise.

In this beauty report, Drug Store News takes a deeper dive into some of the leading trends that are reshaping beauty.more ...

IN THIS ISSUE

In this issue, DSN examines PricewaterhouseCoopers' "Top Health Industry Issues for 2015;" takes you on a tour of Murad, shares beauty trends and insights and delves into location-based technology and how it is revolutionizing health, retail.Click here to view the issue.